Bone News and Research

RSS

H2S transforms dental pulp stem cells into liver cells

Japanese scientists have found that the odorous compound responsible for halitosis - otherwise known as bad breath - is ideal for harvesting stem cells taken from human dental pulp.

27 Feb 2012

MGH scientists isolate OSCs from ovaries of reproductive age women

For the first time, Massachusetts General Hospital (MGH) researchers have isolated egg-producing stem cells from the ovaries of reproductive age women and shown these cells can produce what appear to be normal egg cells or oocytes.

27 Feb 2012

Researchers identify elusive gene responsible for TAR syndrome

Researchers have identified an elusive gene responsible for Thrombocytopenia with Absent Radii (TAR), a rare inherited blood and skeletal disorder. As a result, this research is now being transformed into a medical test that allows prenatal diagnosis and genetic counselling in affected families.

27 Feb 2012

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

Blue Belt's Navio PFS System receives CE Mark approval

Blue Belt Technologies, Inc., a medical device company focused on developing the next generation of "smart" surgical instruments providing precise robotic control for use initially in orthopedic procedures and then for other surgical specialties including neurosurgery, spinal and otolaryngology, announced today that it has received CE Mark for the Navio™ PFS System.

24 Feb 2012

Kidney failure patients may benefit from frequent and longer dialysis treatments

Frequent and longer dialysis treatments may provide more benefits for patients than conventional dialysis treatments, according to several studies appearing in upcoming issues of the Journal of the American Society Nephrology.

24 Feb 2012

Scientists identify specific mechanisms by which vitamin D inhibits inflammation

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling.

24 Feb 2012

IOF-ESCEO 2nd pre-clinical symposium to be held in March, 2012

Attend the most important bone event in Europe - almost 700 abstracts received !

23 Feb 2012

Self-propelled devices through the bloodstream a reality

Someday, your doctor may turn to you and say, "Take two surgeons and call me in the morning." If that day arrives, you may just have Ada Poon to thank.

23 Feb 2012

Pediatricians should screen all children for vitamin D deficiency

As study after study shows the fundamental role vitamin D plays in disease and health, vitamin D deficiency — which often develops insidiously in childhood — should be on every parent's and pediatrician's radar, say physicians from the Johns Hopkins Children's Center.

23 Feb 2012

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid) and low dose dexamethasone in patients with relapsed multiple myeloma.

23 Feb 2012

Targeting versican protein may help stop breast cancer metastasis

Oncologists have known that in order for cancer cells to spread, they must transform themselves so they can detach from a tumor and spread to a distant organ. Now, scientists at Weill Cornell Medical College have revealed critical steps in what happens next -- how these cells reverse the process, morphing back into classical cancer that can now grow into a new tumor.

23 Feb 2012

IDRI launches LEISH-F3 + GLA-SE Phase 1 trial for kala-azar

The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

23 Feb 2012

Osseon's new vertebral augmentation device receives European CE Mark approval

Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.

22 Feb 2012

People with celiac disease are at risk for osteoporosis

People with celiac disease are at risk for osteoporosis, according to physicians at Loyola University Health System (LUHS). A 2009 New England Journal of Medicine study supports this correlation. Researchers believe that people with celiac disease may develop osteoporosis because their body poorly absorbs calcium and vitamin D, which are necessary for bone health.

22 Feb 2012

FDA approves new supplies of drugs that are facing shortages

The United States Food and Drugs Administration (FDA) have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been concerning patients and families particularly of the children with leukemia. But there are currently 283 separate prescription drugs in short supply or unavailable nationwide, and regulators and manufacturers say shortages are a long-term problem that will continue to scare patients and doctors.

22 Feb 2012

ASH releases statement on FDA actions to alleviate drug shortages

The American Society of Hematology is encouraged by the steps FDA is taking to alleviate drug shortages that have significantly affected so many patients with hematologic malignancies under our members' care.

22 Feb 2012

Cedars-Sinai scientist to study potential treatments for AD

A Cedars-Sinai research scientist has been awarded two national grants totaling more than $2.5 million, including a prestigious Research Project Grant from the National Institutes of Health to study potential treatments for Alzheimer's disease.

21 Feb 2012

Genomic instability allows malignant cells to acquire more deadly characteristics

Genomic instability caused by an erosion of the protective caps on chromosomes, followed by activation of an enzyme that reinforces those aps, allows malignant cells to evade destruction and acquire more deadly characteristics, researchers report in an Online Now article at the journal Cell.

21 Feb 2012